BI Expands Biomanufacturing Capacity in Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BI Expands Biomanufacturing Capacity in Europe


ePT--the Electronic Newsletter of Pharmaceutical Technology

Boehringer Ingelheim (BI) has announced in a press release the expansion of its biopharmaceutical manufacturing capabilities at its plants in Biberach, Germany and in Vienna, Austria.

The expansion will include cell-culture and microbial-fermentation capacity and support cell-line and process-development services for BI’s contract manufacturing business. BI has invested approximately EUR 17 million ($26.8 million) to expand cGMP cell banking, process science, cell-line development, and quality laboratories at the two sites.

BI expects to use the expanded resources for services that include monoclonal antibody development, product development using BI’s proprietary high-expression systems, and proprietary plasmid DNA platform. In addition, the facilities will support collaborations with Pfenex on Pseudomonas fluorescens bacterial expression technology and with VTU Technology on Pichia pastoris yeast expression technology.

In the company release, Dr. Dorothee Ambrosius, senior vice-president of Biopharmaceuticals Global Process Science, says, “This is another milestone within our contract manufacturing strategy securing technology leadership and towards increased flexibility and customer orientation.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here